Abivax shares rise after expanded share sales amid strong investor demand

Abivax SA

02/07/2026 08:50

** French-listed shares of Abivax ABVX.PA are up 6% after the biotech company raised $800 million in an expanded share sale on Wednesday
** The offering size increased from the initial $600 million after the over-allotment option was exercised in full, bringing the total number of American Depositary Shares (ADSs) issued to 7.36 million
** The offering implies a valuation of nearly $11 billion for Abivax and eases pressure to pursue a near-term sale
** The company held talks with potential buyers in mid-June but uncertainty about safety data in lead drug candidate obefazimod led pharmaceutical companies to wait before any potential transaction
** Abivax U.S.-listed shares closed at $132.56 on the Nasdaq on Wednesday after falling as low as $72.50 last month, following investor concerns over cancer cases reported in the obefazimod  trial
** Shares recovered most losses on earlier this week after additional safety data reassured investors 
** Including today's rise, the group's Paris-listed shares have gained 3.4% YTD, while the stock was down 2.4% YTD at yesterday's close
     

(Reporting by Lucie Barbier)
((Email: lucie.barbier@thomsonreuters.com))